Literature DB >> 12955149

Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.

Byung-Je Sung1, Kwang Yeon Hwang, Young Ho Jeon, J I Lee, Yong-Seok Heo, Jin Hwan Kim, Jinho Moon, Jung Min Yoon, Young-Lan Hyun, Eunmi Kim, Sung Jin Eum, Sam-Yong Park, Jie-Oh Lee, Tae Gyu Lee, Seonggu Ro, Joong Myung Cho.   

Abstract

Phosphodiesterases (PDEs) are a superfamily of enzymes that degrade the intracellular second messengers cyclic AMP and cyclic GMP. As essential regulators of cyclic nucleotide signalling with diverse physiological functions, PDEs are drug targets for the treatment of various diseases, including heart failure, depression, asthma, inflammation and erectile dysfunction. Of the 12 PDE gene families, cGMP-specific PDE5 carries out the principal cGMP-hydrolysing activity in human corpus cavernosum tissue. It is well known as the target of sildenafil citrate (Viagra) and other similar drugs for the treatment of erectile dysfunction. Despite the pressing need to develop selective PDE inhibitors as therapeutic drugs, only the cAMP-specific PDE4 structures are currently available. Here we present the three-dimensional structures of the catalytic domain (residues 537-860) of human PDE5 complexed with the three drug molecules sildenafil, tadalafil (Cialis) and vardenafil (Levitra). These structures will provide opportunities to design potent and selective PDE inhibitors with improved pharmacological profiles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12955149     DOI: 10.1038/nature01914

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  54 in total

Review 1.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

2.  Ultrafast protein structure-based virtual screening with Panther.

Authors:  Sanna P Niinivehmas; Kari Salokas; Sakari Lätti; Hannu Raunio; Olli T Pentikäinen
Journal:  J Comput Aided Mol Des       Date:  2015-09-25       Impact factor: 3.686

3.  Synthesis and molecular modeling of novel tetrahydro-β-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties.

Authors:  Heba A Mohamed; Nancy M R Girgis; Rainer Wilcken; Matthias R Bauer; Heather N Tinsley; Bernard D Gary; Gary A Piazza; Frank M Boeckler; Ashraf H Abadi
Journal:  J Med Chem       Date:  2010-12-28       Impact factor: 7.446

4.  Characterization of a catalytic ligand bridging metal ions in phosphodiesterases 4 and 5 by molecular dynamics simulations and hybrid quantum mechanical/molecular mechanical calculations.

Authors:  Ying Xiong; Hai-Ting Lu; Yongjian Li; Guang-Fu Yang; Chang-Guo Zhan
Journal:  Biophys J       Date:  2006-09-01       Impact factor: 4.033

Review 5.  The retinal cGMP phosphodiesterase gamma-subunit - a chameleon.

Authors:  Lian-Wang Guo; Arnold E Ruoho
Journal:  Curr Protein Pept Sci       Date:  2008-12       Impact factor: 3.272

6.  The structure of the GAF A domain from phosphodiesterase 6C reveals determinants of cGMP binding, a conserved binding surface, and a large cGMP-dependent conformational change.

Authors:  Sergio E Martinez; Clemens C Heikaus; Rachel E Klevit; Joseph A Beavo
Journal:  J Biol Chem       Date:  2008-07-09       Impact factor: 5.157

7.  Structural basis for the catalytic mechanism of human phosphodiesterase 9.

Authors:  Shenping Liu; Mahmoud N Mansour; Keith S Dillman; Jose R Perez; Dennis E Danley; Paul A Aeed; Samuel P Simons; Peter K Lemotte; Frank S Menniti
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

8.  Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit.

Authors:  Brandy Barren; Lokesh Gakhar; Hakim Muradov; Kimberly K Boyd; S Ramaswamy; Nikolai O Artemyev
Journal:  EMBO J       Date:  2009-10-01       Impact factor: 11.598

9.  Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6.

Authors:  Karyn B Cahill; Jonathan H Quade; Karen L Carleton; Rick H Cote
Journal:  J Biol Chem       Date:  2012-10-02       Impact factor: 5.157

10.  Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.

Authors:  Haroldo A Toque; Fernanda B M Priviero; Saiprasad M Zemse; Edson Antunes; Cleber E Teixeira; R Clinton Webb
Journal:  Clin Exp Pharmacol Physiol       Date:  2008-10-15       Impact factor: 2.557

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.